ASCO 2022 | Consolidative radiotherapy for oligometastatic HER2-negative esophageal and gastric adenocarcinoma.

Nataliya Uboha, MD, PhD, University of Wisconsin, Madison, WI, provides an overview of a Phase III study (NCT04248452) of consolidative radiotherapy in patients with oligometastatic HER2-negative esophageal and gastric adenocarcinoma. Phase II studies on other metastatic cancers with a limited number of metastatic sites have demonstrated a benefit from the addition of radiation to standard systemic therapy. This Phase III study is aiming to determine whether the role of consolidation radiation therapy is also beneficial for patients with oligometastatic HER2-negative esophageal and gastric adenocarcinoma, with a primary endpoint of overall-survival (OS). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.